• 药物临床观察 • 上一篇    下一篇

紫杉醇,奥沙利铂和氟尿嘧啶联合治疗晚期胃癌的疗效分析

张彤   

  1. 新乡市中心医院
  • 收稿日期:2012-03-30 修回日期:2012-10-19 出版日期:2013-02-15 发布日期:2013-02-15
  • 通讯作者: 张彤

A retrospective analysis of Paclitaxel plus Oxaliplatin and Fluorouracil in the treatment of advanced gastric cancer of 94 cases

  • Received:2012-03-30 Revised:2012-10-19 Published:2013-02-15 Online:2013-02-15

摘要: 【摘要】 背景和目的:近年来不断有研究报道显示紫杉醇联合奥沙利铂方案可以提高晚期胃癌的有效率和生存期,不良反应可耐受。当与氟尿嘧啶联合使用时具有协同作用。本组应用紫杉醇,奥沙利铂,氟尿嘧啶方案治疗进展期胃癌患者,旨在探讨此方案治疗进展期胃癌的临床疗效和不良反应。方法:本科自2005年1月至2010年1月共入选94例患者。均为进展期胃癌病人。化疗方案剂量及方法设定:紫杉醇 PTX 135 mg/m2 d1,氟尿嘧啶 5-Fu 500 mg/m2,化疗泵静脉持续静滴 d2-6 , 奥沙利铂 100mg/m2,静脉滴注3h,第2天;紫杉醇使用前严格按照说明书进行预处理。21天为 1个周期 ,2 个周期后评价疗效。结果:全组94例患者总有效率为52.1%(49/94),其中完全缓解率为1.0%(1/94),部分缓解率为51.1%(48/94),稳定23.4%(22/94),进展24.5%(23/94)。中位进展时间7.2个月,中位生存时间11.3 个月。无治疗相关死亡,主要毒性反应为外周血细胞下降、消化道反应、脱发及外周神经毒性。结论:紫杉醇,奥沙利铂,氟尿嘧啶方案治疗进展期胃癌疗效确切,可使患者病情进展延缓,且毒性可耐受,有临床应用价值。

关键词: 进展期胃癌, 紫衫醇, 草酸铂, 氟尿嘧啶, 联合化疗

Abstract: [Abstract] Objective: In recent years there have been research reports indicate that paclitaxel oxaliplatin can improve the efficiency of advanced gastric cancer and survival, adverse reactions can be tolerated. And oxaliplatin combination with fluorouracil have synergistic effects. This group of paclitaxel, oxaliplatin, fluorouracil is in the treatment of advanced gastric cancer, aims to explore the Clinical efficacy of advanced gastric cancer and adverse reactions. Methods: Undergraduate from January 2005 to January 2010, 94 advanced gastric cancer patients were enrolled. Chemotherapy dose and method of setting: paclitaxel (PTX )135 mg/m2 d1, fluorouracil (5-Fu) 500 mg/m2, intravenous continuous infusion chemotherapy pump d2-6, oxaliplatin 100mg/m2, intravenously 3h, d2. strict accordance with the instructions before using paclitaxel pretreatment. 21 days for one cycle, two cycles were evaluated.. Results: Whole group of 94 patients total effective rate was 52.1% (49/94), complete response rate was 1.0% (1 / 94), partial remission rate was 51.1% (48/94), stable was 23.4% (22/94) , progress was 24.5% (23/94). The median time to progression was 7.2 months, median survival time of 11.3 months. No treatment-related deaths, mainly in peripheral blood cells to decrease toxicity, gastrointestinal reactions, alopecia and peripheral neurotoxicity..Conclusions: Paclitaxel, oxaliplatin, fluorouracil in the treatment of advanced gastric cancer is effective, patients can delay disease progression, and toxicity can be tolerated, has clinical value.

Key words: Advanced gastric cancer, paclitaxel, oxaliplatin, fluorouracil, combination chemotherapy